{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:41:42Z","timestamp":1761986502740,"version":"3.37.3"},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T00:00:00Z","timestamp":1494892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Prostaglandin D<jats:sub>2<\/jats:sub> (<jats:styled-content style=\"fixed-case\">PGD<\/jats:styled-content><jats:sub>2<\/jats:sub>) is primarily produced by mast cells and is contributing to the nasal symptoms including nasal obstruction and rhinorrhea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to evaluate the efficacy and safety of a novel <jats:styled-content style=\"fixed-case\">PGD<\/jats:styled-content><jats:sub>2<\/jats:sub> receptor 1 (<jats:styled-content style=\"fixed-case\">DP<\/jats:styled-content>1) antagonist, <jats:styled-content style=\"fixed-case\">ONO<\/jats:styled-content>\u20104053, in patients with seasonal allergic rhinitis (<jats:styled-content style=\"fixed-case\">SAR<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was a multicenter, randomized, double\u2010blind, parallel\u2010group study of patients with <jats:styled-content style=\"fixed-case\">SAR<\/jats:styled-content>. Following a one\u2010week period of placebo run\u2010in, patients who met the study criteria were randomized to either the <jats:styled-content style=\"fixed-case\">ONO<\/jats:styled-content>\u20104053, leukotriene receptor antagonist pranlukast, or placebo group for a two\u2010week treatment period. A total of 200 patients were planned to be randomly assigned to receive <jats:styled-content style=\"fixed-case\">ONO<\/jats:styled-content>\u20104053, pranlukast, or placebo in a 2:2:1 ratio. Nasal and eye symptoms were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both <jats:styled-content style=\"fixed-case\">ONO<\/jats:styled-content>\u20104053 and pranlukast had higher efficacy than placebo on all nasal and eye symptoms. <jats:styled-content style=\"fixed-case\">ONO<\/jats:styled-content>\u20104053 outperformed pranlukast in a total of three nasal symptom scores (T3<jats:styled-content style=\"fixed-case\">NSS<\/jats:styled-content>) as well as in individual scores for sneezing, rhinorrhea, and nasal itching. For T3<jats:styled-content style=\"fixed-case\">NSS<\/jats:styled-content>, the Bayesian posterior probabilities that pranlukast was better than placebo and <jats:styled-content style=\"fixed-case\">ONO<\/jats:styled-content>\u20104053 was better than pranlukast were 70.0% and 81.6%, respectively, suggesting that <jats:styled-content style=\"fixed-case\">ONO<\/jats:styled-content>\u20104053 has a higher efficacy compared with pranlukast. There was no safety\u2010related issue in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We demonstrated that the efficacy of <jats:styled-content style=\"fixed-case\">ONO<\/jats:styled-content>\u20104053 was greater than that of pranlukast with a similar safety profile. This study indicates the potential of <jats:styled-content style=\"fixed-case\">ONO<\/jats:styled-content>\u20104053 for use as a treatment for <jats:styled-content style=\"fixed-case\">SAR<\/jats:styled-content> (Japic<jats:styled-content style=\"fixed-case\">CTI<\/jats:styled-content>\u2010142706).<\/jats:p><\/jats:sec>","DOI":"10.1111\/all.13174","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T17:27:21Z","timestamp":1491413241000},"page":"1565-1575","source":"Crossref","is-referenced-by-count":17,"title":["A randomized controlled phase <scp>II<\/scp> clinical trial comparing <scp>ONO<\/scp>\u20104053, a novel <scp>DP<\/scp>1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis"],"prefix":"10.1111","volume":"72","author":[{"given":"K.","family":"Okubo","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology Nippon Medical School Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hashiguchi","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Futaba Clinic Tokyo Japan"},{"name":"Medical Corporation Shinanokai Samoncho Clinic Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Takeda Clinic Saitama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Takasaka Clinic Saitama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kitagoh","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Kitagoh Clinic Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Miho","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Miho Clinic Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Tomomatsu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Tomomatsu Clinic Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratories III Ono Pharmaceutical Co., Ltd. Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Odani","sequence":"additional","affiliation":[{"name":"Data Science Ono Pharmaceutical Co., Ltd. Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1960-9257","authenticated-orcid":false,"given":"H.","family":"Yamamotoya","sequence":"additional","affiliation":[{"name":"Translational Science Ono Pharmaceutical Co., Ltd. Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01620.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.06.003"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.14-RAI-0768"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0194599814561600"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.129.4.1627"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2266"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2006.02.005"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.08.003"},{"key":"e_1_2_9_10_1","first-page":"195","article-title":"Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting","volume":"19","author":"Yonekura S","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/21556660.2012.703630"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.O-08-533"},{"volume-title":"Nasal Allergies: Basics and Clinical \u2010 Revised Edition [in Japanese]","year":"2005","author":"Okuda M","key":"e_1_2_9_13_1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.O-07-515"},{"key":"e_1_2_9_15_1","first-page":"98","article-title":"A comparative study of mometasone furoate nasal spray and fluticasone propionate nasal spray in patients with perennial allergic rhinitis","volume":"16","author":"Soh N","year":"2009","journal-title":"Allergol Immunol"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/00016480510026944"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.344"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603668"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1989.tb11816.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112233"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1996.tb00552.x"},{"key":"e_1_2_9_22_1","first-page":"252","article-title":"Effects of intensity of early response to allergen on the late phase of both the nose and skin","volume":"73","author":"Small P","year":"1994","journal-title":"Ann Allergy"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507113130201"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70118-5"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1998.tb03775.x"},{"key":"e_1_2_9_26_1","first-page":"597","article-title":"Mediator release after nasal airway challenge with allergen","volume":"128","author":"Naclerio RM","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80156-3"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb04878.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0211-2"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/2168479014533970"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.07.006"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.7248\/jjrhi1982.38.1_69"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(87)80274-9"},{"key":"e_1_2_9_34_1","first-page":"275","article-title":"Prostaglandin D2 is released during acute allergic bronchospasm in man","volume":"98","author":"Murray JJ","year":"1985","journal-title":"Trans Assoc Am Physicians"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198609253151304"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.52.6.513"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200308-1092OC"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000155743"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00061614"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5460.2013"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.03.003"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fall.13174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.13174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T18:53:52Z","timestamp":1696532032000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.13174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,16]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/all.13174"],"URL":"https:\/\/doi.org\/10.1111\/all.13174","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"type":"print","value":"0105-4538"},{"type":"electronic","value":"1398-9995"}],"subject":[],"published":{"date-parts":[[2017,5,16]]}}}